Literature DB >> 10420082

Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: implications for clinical reverse use-dependent effects.

L Lai1, M Su, Y Tseng, W Lien.   

Abstract

The slow delayed rectifier potassium current (I(Ks)) is unique in its slow activation and deactivation kinetics. It is important during cardiac repolarization, especially when the heart rate is fast. We compared the effects of quinidine, procainamide, sotalol, and amiodarone on I(Ks) and correlated the findings with the clinical reverse use-dependent effects of potassium channel blockers. Human minK RNA was obtained by reverse transcription-polymerase chain reaction using explanted human heart. The RNA was injected into Xenopus oocytes for heterologous expression of I(Ks). A two-electrode voltage clamp technique was performed to investigate the I(Ks). We demonstrated that quinidine, sotalol and procainamide had no effects on I(Ks) up to a concentration of 300 microM while amiodarone inhibited I(Ks) in a concentration-dependent manner starting from 10 microM. The inhibition by amiodarone was state-dependent with gradual unblocking after depolarization. The degree of inhibition was 53% immediately after depolarization and 19% at the end of a 5-second depolarization. I(Ks) is 30 times more sensitive to amiodarone than to quinidine, sotalol, and procainamide. Quinidine, sotalol and procainamide have reverse use-dependent effects while amiodarone does not. This is compatible with the hypothesis that no inhibition of I(Ks) at clinical concentrations contributes to the clinical reverse use-dependent effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10420082     DOI: 10.1007/bf02253566

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  4 in total

Review 1.  Antiarrhythmics--from cell to clinic: past, present, and future.

Authors:  J C Hancox; K C Patel; J V Jones
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

2.  Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.

Authors:  Christian Wolpert; Rainer Schimpf; Carla Giustetto; Charles Antzelevitch; Jonathan Cordeiro; Robert Dumaine; Ramon Brugada; Kui Hong; Urs Bauersfeld; Fiorenzo Gaita; Martin Borggrefe
Journal:  J Cardiovasc Electrophysiol       Date:  2005-01

Review 3.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 4.  Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls.

Authors:  Edward S A Humphries; Caroline Dart
Journal:  J Biomol Screen       Date:  2015-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.